REGN Regeneron Pharmaceuticals
- 1039.110
- -6.260-0.60%
- 1042.510
- +3.400+0.33%
Regeneron Pharmaceuticals News
J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,150
J.P. Morgan analyst Chris Schott maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and adjusts the target price from $1,050 to $1,150.According to TipRanks data, the analyst has a succ
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron Pharmaceuticals Hits All-time High
Regeneron Pharmaceuticals(REGN.US) Director Sells US$1.6 Million in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Director BROWN MICHAEL S sold 1,535 shares of common stock on Jun 14, 2024 at an average price of $1,040 for a total value of $1.6 million.Source: Announcement Wha
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing
Michael S Brown, Director, on June 14, 2024, sold 1,535 shares in Regeneron Pharmaceuticals (REGN) for $1,596,400. Following the Form 4 filing with the SEC, Brown has control over a total of 12,544 sh
New Weight-Loss Drugs and Devices Are Coming This Week
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.
Regeneron Pharma Is Maintained at Overweight by JP Morgan
Regeneron Pharma Is Maintained at Overweight by JP Morgan
Regeneron Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 11.22% JP Morgan $1050 → $1150 Maintains Overweight 06/12/2024 18.86% RBC Capital $1200 → $1229
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050
Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,229, according to analysts polled by eCapital IQ. Price: 1,037.26, Change: +0.74, Percent
Regeneron Pharmaceuticals Says 50% of Patients in Multiple Myeloma Therapy Study Achieved Complete Response
Regeneron Pharmaceuticals (REGN) said Sunday long-term data from an early-to-mid-stage trial of its experimental therapy, linvoseltamab, showed that 50% of patients with relapsed/refractory multiple m
Express News | Regeneron Pharmaceuticals: At 14-Months Median Follow-up in Trial, 50% of Patients Achieved a Complete Response or Better, a 71% Overall Response Rate
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients With Heavily Pre-Treated Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that 14-month median follow-up data from the pivotal Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) were shared during an oral presentation at the European Hematology Association (EHA) Congress 2024 and published in the Journal of Clinical Oncology.
Form 144 | Regeneron Pharmaceuticals(REGN.US) Director Proposes to Sell 1.58 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 14, $Regeneron Pharmaceuticals(REGN.US)$ Director MICHAEL S BROWN intends to sell 1,535 shares of its common stock on Jun 14, with a total market value of approximately $1
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea
Regeneron Pharmaceuticals (REGN) said Friday it won permanent injunctions from a district court against the US launch of Yesafili, which is a biosimilar ophthalmic drug to the company's Eylea product.
Ocular Therapeutix Jumps After Investor Day Updates
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,030
TD Cowen analyst Tyler Van Buren maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,030.According to TipRanks data, the analyst has a success rate o
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) Have Seen Stellar Returns of 220% Over the Past Five Years
Regeneron Pharmaceuticals(REGN.US) Officer Sells US$25.61 Million in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Officer SCHLEIFER LEONARD S sold 25,213 shares of common stock on Jun 11, 12, 2024 at an average price of $1,015.75 for a total value of $25.61 million.Source: Ann
Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing
Leonard S Schleifer, Director, Board Co-Chair, President & CEO, on June 11, 2024, sold 25,213 shares in Regeneron Pharmaceuticals (REGN) for $25,610,229. Following the Form 4 filing with the SEC, Schl
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
RBC Capital Markets analyst Brian Abrahams reiterated an Outperform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), raising the price forecast to $1,299 from $1,200.Abrahams surveyed 31 pulmo
Analysis
Price Target
No Data
